2.95 USD
-0.06 (-1.99%)
Overall EVO gets a fundamental rating of 2 out of 10. We evaluated EVO against 57 industry peers in the Life Sciences Tools & Services industry. EVO may be in some trouble as it scores bad on both profitability and health. EVO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
EVO had negative earnings in the past year.
EVO had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: EVO reported negative net income in multiple years.
EVO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -8.97%, EVO is in line with its industry, outperforming 47.37% of the companies in the same industry.
EVO has a Return On Equity of -19.87%. This is comparable to the rest of the industry: EVO outperforms 49.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.97% | ||
| ROE | -19.87% | ||
| ROIC | N/A |
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 10.82%, EVO is doing worse than 85.96% of the companies in the same industry.
EVO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EVO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 10.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
2. Health
2.1 Basic Checks
EVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EVO has been increased compared to 1 year ago.
Compared to 5 years ago, EVO has more shares outstanding
EVO has a better debt/assets ratio than last year.
2.2 Solvency
EVO has an Altman-Z score of 0.46. This is a bad value and indicates that EVO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.46, EVO is doing worse than 70.18% of the companies in the same industry.
A Debt/Equity ratio of 0.48 indicates that EVO is not too dependend on debt financing.
The Debt to Equity ratio of EVO (0.48) is worse than 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.46 |
ROIC/WACCN/A
WACC7.7%
2.3 Liquidity
EVO has a Current Ratio of 2.12. This indicates that EVO is financially healthy and has no problem in meeting its short term obligations.
EVO's Current ratio of 2.12 is in line compared to the rest of the industry. EVO outperforms 42.11% of its industry peers.
EVO has a Quick Ratio of 2.03. This indicates that EVO is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.03, EVO perfoms like the industry average, outperforming 45.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.12 | ||
| Quick Ratio | 2.03 |
3. Growth
3.1 Past
The earnings per share for EVO have decreased strongly by -136.17% in the last year.
Looking at the last year, EVO shows a decrease in Revenue. The Revenue has decreased by -2.67% in the last year.
EVO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.29% yearly.
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
Revenue 1Y (TTM)-2.67%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-11.36%
3.2 Future
The Earnings Per Share is expected to grow by 18.47% on average over the next years. This is quite good.
Based on estimates for the next years, EVO will show a small growth in Revenue. The Revenue will grow by 5.09% on average per year.
EPS Next Y62.04%
EPS Next 2Y35.73%
EPS Next 3Y27.87%
EPS Next 5Y18.47%
Revenue Next Year-2.75%
Revenue Next 2Y2.87%
Revenue Next 3Y5.64%
Revenue Next 5Y5.09%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for EVO. In the last year negative earnings were reported.
Also next year EVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EVO is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 584.81 |
4.3 Compensation for Growth
EVO's earnings are expected to grow with 27.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.73%
EPS Next 3Y27.87%
5. Dividend
5.1 Amount
EVO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:EVO (12/17/2025, 2:32:02 PM)
2.95
-0.06 (-1.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners54.68%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap1.05B
Revenue(TTM)756.33M
Net Income(TTM)-158.98M
Analysts78.46
Price Target5.35 (81.36%)
Short Float %0.24%
Short Ratio9.25
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-64.24%
Min EPS beat(2)-106.63%
Max EPS beat(2)-21.86%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.97%
Min Revenue beat(2)-9.17%
Max Revenue beat(2)-4.77%
Revenue beat(4)0
Avg Revenue beat(4)-4.99%
Min Revenue beat(4)-9.17%
Max Revenue beat(4)-0.93%
Revenue beat(8)1
Avg Revenue beat(8)-3.74%
Revenue beat(12)4
Avg Revenue beat(12)1.12%
Revenue beat(16)7
Avg Revenue beat(16)2.95%
PT rev (1m)-3.66%
PT rev (3m)-5.26%
EPS NQ rev (1m)137.5%
EPS NQ rev (3m)733.6%
EPS NY rev (1m)5.75%
EPS NY rev (3m)10.5%
Revenue NQ rev (1m)4.39%
Revenue NQ rev (3m)6.28%
Revenue NY rev (1m)-0.49%
Revenue NY rev (3m)-1.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.18 | ||
| P/FCF | N/A | ||
| P/OCF | 630.91 | ||
| P/B | 1.11 | ||
| P/tB | 1.78 | ||
| EV/EBITDA | 584.81 |
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)0
OCFY0.16%
SpS2.51
BVpS2.65
TBVpS1.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.97% | ||
| ROE | -19.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 10.82% | ||
| FCFM | N/A |
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
F-Score4
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 209.82 | ||
| Cap/Depr | 90.72% | ||
| Cap/Sales | 12.19% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 76.3% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.12 | ||
| Quick Ratio | 2.03 | ||
| Altman-Z | 0.46 |
F-Score4
WACC7.7%
ROIC/WACCN/A
Cap/Depr(3y)186.39%
Cap/Depr(5y)182.37%
Cap/Sales(3y)22.79%
Cap/Sales(5y)21.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
EPS Next Y62.04%
EPS Next 2Y35.73%
EPS Next 3Y27.87%
EPS Next 5Y18.47%
Revenue 1Y (TTM)-2.67%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-11.36%
Revenue Next Year-2.75%
Revenue Next 2Y2.87%
Revenue Next 3Y5.64%
Revenue Next 5Y5.09%
EBIT growth 1Y-6.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year131.73%
EBIT Next 3Y48.36%
EBIT Next 5Y33.1%
FCF growth 1Y52.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y107.69%
OCF growth 3Y-46.98%
OCF growth 5Y-15.47%
EVOTEC SE - SPON ADR / EVO FAQ
Can you provide the ChartMill fundamental rating for EVOTEC SE - SPON ADR?
ChartMill assigns a fundamental rating of 2 / 10 to EVO.
What is the valuation status for EVO stock?
ChartMill assigns a valuation rating of 1 / 10 to EVOTEC SE - SPON ADR (EVO). This can be considered as Overvalued.
How profitable is EVOTEC SE - SPON ADR (EVO) stock?
EVOTEC SE - SPON ADR (EVO) has a profitability rating of 2 / 10.
What is the financial health of EVOTEC SE - SPON ADR (EVO) stock?
The financial health rating of EVOTEC SE - SPON ADR (EVO) is 3 / 10.